GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (FRA:45O) » Definitions » Total Receivables

Orgenesis (FRA:45O) Total Receivables : €1.11 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Orgenesis Total Receivables?

Orgenesis's Total Receivables for the quarter that ended in Jun. 2024 was €1.11 Mil.


Orgenesis Total Receivables Historical Data

The historical data trend for Orgenesis's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Total Receivables Chart

Orgenesis Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.83 2.68 17.40 37.60 2.35

Orgenesis Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.42 7.45 2.35 1.25 1.11

Orgenesis Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Orgenesis Total Receivables Related Terms

Thank you for viewing the detailed overview of Orgenesis's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis Business Description

Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.

Orgenesis Headlines

No Headlines